1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Dipeptidyl Peptidase-4 Inhibitors Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Dipeptidyl Peptidase-4 Inhibitors by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Dipeptidyl Peptidase-4 Inhibitors by Country/Region, 2018, 2022 & 2029
2.2 Dipeptidyl Peptidase-4 Inhibitors Segment by Type
2.2.1 Sitagliptin
2.2.2 Saxagliptin
2.2.3 Vildagliptin
2.2.4 Linagliptin
2.2.5 Alogliptin
2.2.6 Other
2.3 Dipeptidyl Peptidase-4 Inhibitors Sales by Type
2.3.1 Global Dipeptidyl Peptidase-4 Inhibitors Sales Market Share by Type (2018-2023)
2.3.2 Global Dipeptidyl Peptidase-4 Inhibitors Revenue and Market Share by Type (2018-2023)
2.3.3 Global Dipeptidyl Peptidase-4 Inhibitors Sale Price by Type (2018-2023)
2.4 Dipeptidyl Peptidase-4 Inhibitors Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Other
2.5 Dipeptidyl Peptidase-4 Inhibitors Sales by Application
2.5.1 Global Dipeptidyl Peptidase-4 Inhibitors Sale Market Share by Application (2018-2023)
2.5.2 Global Dipeptidyl Peptidase-4 Inhibitors Revenue and Market Share by Application (2018-2023)
2.5.3 Global Dipeptidyl Peptidase-4 Inhibitors Sale Price by Application (2018-2023)
3 Global Dipeptidyl Peptidase-4 Inhibitors by Company
3.1 Global Dipeptidyl Peptidase-4 Inhibitors Breakdown Data by Company
3.1.1 Global Dipeptidyl Peptidase-4 Inhibitors Annual Sales by Company (2018-2023)
3.1.2 Global Dipeptidyl Peptidase-4 Inhibitors Sales Market Share by Company (2018-2023)
3.2 Global Dipeptidyl Peptidase-4 Inhibitors Annual Revenue by Company (2018-2023)
3.2.1 Global Dipeptidyl Peptidase-4 Inhibitors Revenue by Company (2018-2023)
3.2.2 Global Dipeptidyl Peptidase-4 Inhibitors Revenue Market Share by Company (2018-2023)
3.3 Global Dipeptidyl Peptidase-4 Inhibitors Sale Price by Company
3.4 Key Manufacturers Dipeptidyl Peptidase-4 Inhibitors Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Dipeptidyl Peptidase-4 Inhibitors Product Location Distribution
3.4.2 Players Dipeptidyl Peptidase-4 Inhibitors Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Dipeptidyl Peptidase-4 Inhibitors by Geographic Region
4.1 World Historic Dipeptidyl Peptidase-4 Inhibitors Market Size by Geographic Region (2018-2023)
4.1.1 Global Dipeptidyl Peptidase-4 Inhibitors Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Dipeptidyl Peptidase-4 Inhibitors Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Dipeptidyl Peptidase-4 Inhibitors Market Size by Country/Region (2018-2023)
4.2.1 Global Dipeptidyl Peptidase-4 Inhibitors Annual Sales by Country/Region (2018-2023)
4.2.2 Global Dipeptidyl Peptidase-4 Inhibitors Annual Revenue by Country/Region (2018-2023)
4.3 Americas Dipeptidyl Peptidase-4 Inhibitors Sales Growth
4.4 APAC Dipeptidyl Peptidase-4 Inhibitors Sales Growth
4.5 Europe Dipeptidyl Peptidase-4 Inhibitors Sales Growth
4.6 Middle East & Africa Dipeptidyl Peptidase-4 Inhibitors Sales Growth
5 Americas
5.1 Americas Dipeptidyl Peptidase-4 Inhibitors Sales by Country
5.1.1 Americas Dipeptidyl Peptidase-4 Inhibitors Sales by Country (2018-2023)
5.1.2 Americas Dipeptidyl Peptidase-4 Inhibitors Revenue by Country (2018-2023)
5.2 Americas Dipeptidyl Peptidase-4 Inhibitors Sales by Type
5.3 Americas Dipeptidyl Peptidase-4 Inhibitors Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Dipeptidyl Peptidase-4 Inhibitors Sales by Region
6.1.1 APAC Dipeptidyl Peptidase-4 Inhibitors Sales by Region (2018-2023)
6.1.2 APAC Dipeptidyl Peptidase-4 Inhibitors Revenue by Region (2018-2023)
6.2 APAC Dipeptidyl Peptidase-4 Inhibitors Sales by Type
6.3 APAC Dipeptidyl Peptidase-4 Inhibitors Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Dipeptidyl Peptidase-4 Inhibitors by Country
7.1.1 Europe Dipeptidyl Peptidase-4 Inhibitors Sales by Country (2018-2023)
7.1.2 Europe Dipeptidyl Peptidase-4 Inhibitors Revenue by Country (2018-2023)
7.2 Europe Dipeptidyl Peptidase-4 Inhibitors Sales by Type
7.3 Europe Dipeptidyl Peptidase-4 Inhibitors Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Dipeptidyl Peptidase-4 Inhibitors by Country
8.1.1 Middle East & Africa Dipeptidyl Peptidase-4 Inhibitors Sales by Country (2018-2023)
8.1.2 Middle East & Africa Dipeptidyl Peptidase-4 Inhibitors Revenue by Country (2018-2023)
8.2 Middle East & Africa Dipeptidyl Peptidase-4 Inhibitors Sales by Type
8.3 Middle East & Africa Dipeptidyl Peptidase-4 Inhibitors Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Dipeptidyl Peptidase-4 Inhibitors
10.3 Manufacturing Process Analysis of Dipeptidyl Peptidase-4 Inhibitors
10.4 Industry Chain Structure of Dipeptidyl Peptidase-4 Inhibitors
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Dipeptidyl Peptidase-4 Inhibitors Distributors
11.3 Dipeptidyl Peptidase-4 Inhibitors Customer
12 World Forecast Review for Dipeptidyl Peptidase-4 Inhibitors by Geographic Region
12.1 Global Dipeptidyl Peptidase-4 Inhibitors Market Size Forecast by Region
12.1.1 Global Dipeptidyl Peptidase-4 Inhibitors Forecast by Region (2024-2029)
12.1.2 Global Dipeptidyl Peptidase-4 Inhibitors Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Dipeptidyl Peptidase-4 Inhibitors Forecast by Type
12.7 Global Dipeptidyl Peptidase-4 Inhibitors Forecast by Application
13 Key Players Analysis
13.1 Merck
13.1.1 Merck Company Information
13.1.2 Merck Dipeptidyl Peptidase-4 Inhibitors Product Portfolios and Specifications
13.1.3 Merck Dipeptidyl Peptidase-4 Inhibitors Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Merck Main Business Overview
13.1.5 Merck Latest Developments
13.2 Boehringer Ingelheim
13.2.1 Boehringer Ingelheim Company Information
13.2.2 Boehringer Ingelheim Dipeptidyl Peptidase-4 Inhibitors Product Portfolios and Specifications
13.2.3 Boehringer Ingelheim Dipeptidyl Peptidase-4 Inhibitors Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Boehringer Ingelheim Main Business Overview
13.2.5 Boehringer Ingelheim Latest Developments
13.3 AstraZeneca
13.3.1 AstraZeneca Company Information
13.3.2 AstraZeneca Dipeptidyl Peptidase-4 Inhibitors Product Portfolios and Specifications
13.3.3 AstraZeneca Dipeptidyl Peptidase-4 Inhibitors Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 AstraZeneca Main Business Overview
13.3.5 AstraZeneca Latest Developments
13.4 Takeda Pharmaceutical
13.4.1 Takeda Pharmaceutical Company Information
13.4.2 Takeda Pharmaceutical Dipeptidyl Peptidase-4 Inhibitors Product Portfolios and Specifications
13.4.3 Takeda Pharmaceutical Dipeptidyl Peptidase-4 Inhibitors Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Takeda Pharmaceutical Main Business Overview
13.4.5 Takeda Pharmaceutical Latest Developments
13.5 Novartis
13.5.1 Novartis Company Information
13.5.2 Novartis Dipeptidyl Peptidase-4 Inhibitors Product Portfolios and Specifications
13.5.3 Novartis Dipeptidyl Peptidase-4 Inhibitors Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Novartis Main Business Overview
13.5.5 Novartis Latest Developments
13.6 Jiangsu Hansoh Pharmaceutical
13.6.1 Jiangsu Hansoh Pharmaceutical Company Information
13.6.2 Jiangsu Hansoh Pharmaceutical Dipeptidyl Peptidase-4 Inhibitors Product Portfolios and Specifications
13.6.3 Jiangsu Hansoh Pharmaceutical Dipeptidyl Peptidase-4 Inhibitors Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Jiangsu Hansoh Pharmaceutical Main Business Overview
13.6.5 Jiangsu Hansoh Pharmaceutical Latest Developments
13.7 Qilu Pharmaceutical
13.7.1 Qilu Pharmaceutical Company Information
13.7.2 Qilu Pharmaceutical Dipeptidyl Peptidase-4 Inhibitors Product Portfolios and Specifications
13.7.3 Qilu Pharmaceutical Dipeptidyl Peptidase-4 Inhibitors Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Qilu Pharmaceutical Main Business Overview
13.7.5 Qilu Pharmaceutical Latest Developments
13.8 Beijing Tide Pharmaceutical
13.8.1 Beijing Tide Pharmaceutical Company Information
13.8.2 Beijing Tide Pharmaceutical Dipeptidyl Peptidase-4 Inhibitors Product Portfolios and Specifications
13.8.3 Beijing Tide Pharmaceutical Dipeptidyl Peptidase-4 Inhibitors Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Beijing Tide Pharmaceutical Main Business Overview
13.8.5 Beijing Tide Pharmaceutical Latest Developments
13.9 CTTQ
13.9.1 CTTQ Company Information
13.9.2 CTTQ Dipeptidyl Peptidase-4 Inhibitors Product Portfolios and Specifications
13.9.3 CTTQ Dipeptidyl Peptidase-4 Inhibitors Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 CTTQ Main Business Overview
13.9.5 CTTQ Latest Developments
13.10 Jiangsu Deyuan Pharmaceutical
13.10.1 Jiangsu Deyuan Pharmaceutical Company Information
13.10.2 Jiangsu Deyuan Pharmaceutical Dipeptidyl Peptidase-4 Inhibitors Product Portfolios and Specifications
13.10.3 Jiangsu Deyuan Pharmaceutical Dipeptidyl Peptidase-4 Inhibitors Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Jiangsu Deyuan Pharmaceutical Main Business Overview
13.10.5 Jiangsu Deyuan Pharmaceutical Latest Developments
13.11 Jiujiang Zhongtian Pharmaceutical
13.11.1 Jiujiang Zhongtian Pharmaceutical Company Information
13.11.2 Jiujiang Zhongtian Pharmaceutical Dipeptidyl Peptidase-4 Inhibitors Product Portfolios and Specifications
13.11.3 Jiujiang Zhongtian Pharmaceutical Dipeptidyl Peptidase-4 Inhibitors Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Jiujiang Zhongtian Pharmaceutical Main Business Overview
13.11.5 Jiujiang Zhongtian Pharmaceutical Latest Developments
13.12 Yabao Pharmaceutical
13.12.1 Yabao Pharmaceutical Company Information
13.12.2 Yabao Pharmaceutical Dipeptidyl Peptidase-4 Inhibitors Product Portfolios and Specifications
13.12.3 Yabao Pharmaceutical Dipeptidyl Peptidase-4 Inhibitors Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Yabao Pharmaceutical Main Business Overview
13.12.5 Yabao Pharmaceutical Latest Developments
14 Research Findings and Conclusion
| ※参考情報 ジペプチジルペプチダーゼ-4阻害剤（DPP-4阻害剤）は、主に糖尿病の治療に用いられる薬剤の一群であり、最近の薬理学の進展により、非常に注目されています。この薬剤は、体内でのインクレチンというホルモンの作用を強化し、血糖値のコントロールに寄与します。 まず、ジペプチジルペプチダーゼ-4（DPP-4）は、インクレチンホルモンの分解を担う酵素です。インクレチンホルモンには、主にグルカゴン様ペプチド-1（GLP-1）とグルコース依存性インスリン分泌ポリペプチド（GIP）の2種類があります。これらのホルモンは、食事後に分泌され、インスリンの分泌を促進するとともに、グルカゴンの分泌を抑制し、血糖値を低下させる作用があります。しかし、DPP-4はこれらのホルモンを迅速に分解するため、血糖値の制御が不十分になることがあります。DPP-4阻害剤は、この酵素の働きを阻害することで、インクレチンホルモンの濃度を高め、血糖値を適正な範囲に保つことを目的としています。 この薬剤の特徴としては、低血糖のリスクが比較的低いことが挙げられます。DPP-4阻害剤は、食事から得られる糖の吸収状況や、インスリンの必要量に応じて、血糖値を調整するため、過剰なインスリン分泌による低血糖を引き起こしにくいのです。また、体重増加のリスクも低いため、特に肥満患者に対する治療の選択肢として有効です。 DPP-4阻害剤にはいくつかの種類があり、それぞれに特有の性質があります。主要なDPP-4阻害剤としては、シタグリプチン（Sitagliptin）、サクサグリプチン（Saxagliptin）、リナグリプチン（Linagliptin）、アログリプチン（Alogliptin）などがあります。これらの薬剤は、作用機序は同じですが、それぞれの副作用や薬物相互作用、投与頻度などに差異があります。例えば、リナグリプチンは、主に肝臓で代謝されるため、腎機能に影響を受けにくい利点があります。一方、サクサグリプチンは、腎によって排泄されるため、腎機能に留意が必要です。 用途としては、主に2型糖尿病の治療に用いられます。DPP-4阻害剤は、メトホルミンやスルホニルウレアなどの他の経口血糖降下薬と併用されることが多く、個々の患者の状況に応じて、最適な治療法を選択します。特に、これらの薬剤は、インスリン治療を必要としない患者や、血糖コントロールが不十分な患者に対して有効性があります。 関連技術としては、新しいDPP-4阻害剤の開発だけでなく、インクレチンアナログやGLP-1受容体作動薬の開発も進められています。これらの薬剤は、インクレチンホルモンの受容体に直接作用し、より強力な血糖低下効果を持ちます。さらに、DPP-4阻害剤とその他の治療法とを組み合わせることにより、より効果的な血糖コントロールが期待されています。 DPP-4阻害剤は、糖尿病治療の中でも比較的新しい治療手段であり、患者にとっての生活の質を向上させる可能性を秘めています。しかし、導入にあたっては、必ず医師の監督の下で行われるべきであり、患者の状態や基礎疾患を考慮した上での判断が求められます。 これらの薬剤は、副作用としては消化器系の症状（悪心、嘔吐、下痢など）や、アレルギー反応、特に皮膚の発疹などが挙げられます。まれに、急性膵炎との関連も示唆されているため、患者は使用中の症状に注意し、異常を感じた場合には速やかに医療機関を受診することが必要です。 今後の研究では、DPP-4阻害剤の他の疾患への応用や、その長期的な安全性と有効性についても注目されていくでしょう。特に、心血管疾患や腎疾患との関連性についてはより深く検討されることが期待され、糖尿病治療における総合的なアプローチの一部としてのDPP-4阻害剤の位置づけが明確になっていくことが望まれます。 このように、ジペプチジルペプチダーゼ-4阻害剤は、糖尿病治療の中で重要な役割を果たしており、その特性や違いを理解することで、効果的な治療戦略が立てられるでしょう。患者それぞれのニーズに合わせた治療が求められる中で、DPP-4阻害剤はその一助となることが期待されます。 |
